First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649 Meeting Abstract
| Authors: | Moehler, M. H.; Shitara, K.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. S. C.; Liu, T.; Schenker, M.; Yanez, P. E.; Tehfe, M.; Li, M.; Cullen, D.; Memaj, A.; Lei, M.; Xiao, H.; Janjigian, Y. Y.; Ajani, J. A. |
| Abstract Title: | First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649 |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602104 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4002 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4002 -- Source: Wos |
